Post-mortem analysis of limited blood samples from Huntington’s disease patients has found elevated AKT protein levels in their lymphoblasts, and elevated Akt1 has been documented in monocytes generated from experimental disease models prior to disease development and during neurodegeneration, therefore, correlating changes in AKT activity to disease onset [156, 157]. The gene discussed is AKT1; the disease is juvenile Huntington disease.